ࡱ> ac`7 !+bjbjUU %t7|7|!'ldddddddx~~~~dx$,        #######$B& b(#d     #> dd  #> > > d d #> #> > 6!t!dd#  `FJx~R###0$# )> )#> xxddddClinical Presentation in Elderly Claus is an 86-year-old man with a history of two MIs thirty years ago, bypass surgery 25 years ago, pacemaker 15 years ago, inplanted defibrillator and carotid artery surgery 10 years ago, known ejection fraction of 14 percent. He was going to an exercise program until he fell. Now he is too tired and having trouble making decisions. His wife notes increased coughing at night. CHF in the Homebound Elderly Patricia J. Gifford, MD Lumetra 2006 Clinical Presentation in Elderly (cont.) Exam revealed dullness left base, pleural effusion on CXR. New hypoxia to 86% with ambulation. Repeat echo: EF=11%. BNP up to 500 from 150. New ankle and liver swelling, decreased appetite. Using walker and scooter, several falls. The Scope of the Problem Is Enormous! Fastest growing cardiac illness 2 percent of the population 1 million hospitalizations annually Six-day stay average; 50 percent rehospitalization $23 billion hospital/$40 billion outpatient 5-year mortality is 50 percent Am Heart Journal, Jan 2000 Whos Affected African-Americans, Latinos, Native Americans have highest rates Men and women equal; women are later International problem Industrialized countries: atherosclerosis, HTN Underdeveloped: Chagas disease Defining CHF: Systolic vs. Diastolic Failure of heart to meet the metabolic needs of tissue; and/or need to pump at abnormally high filling pressures Systolic failure begins as failure of muscle contractility Diastolic failure begins as failure of muscle relaxation Both generate the same cascade of endocrine changes: elevated norepinephrine, activation of the renin-angiotensin system, increase in natriuretic peptides Etiologies of Systolic CHF Atheroclerotic disease Multiple myocardial infarctions Myocardial ischemia Valvular disease: volume overload Regurgitant valves increased filling pressures Tricuspid regurgitation: right-sided failure Mitral regurgitation: left-sided failure Etiologies of Diastolic CHF Hypertension Stiff myocardium, increased LV mass Valvular disease: pressure overload Aortic stenosis Infiltrative diseases Amyloidosis Hypertrophic cariomyopathy Other Contributors Arrhythmias: atrial fibrillation Reduces cardiac output by 1/3 in elderly Requires anticoagulation Comorbidities: Diabetes / renal failure COPD Anemia General deconditioning Dementia /inability to take meds and modify diet appropriately Staging of CHF: New York Heart Association Class I: No limitations on function Class II: Limitation on strenuous activity Class III: Limitation on ordinary activity. Comfortable at rest Class IV: Breathless, tired, palpitations at rest Making the Diagnosis History Atypical presentation is typical for geriatrics Rare complaints of shortness of breath, pain Fatigue is most common complaint Ankle and abdominal pants are tight swelling Poor appetite; weight loss Increased confusion; depression General functional decline; sleep disorders Making the Diagnosis (cont.) Physical exam: establish a baseline then be alert to changes Modified by co-morbidities: diabetes, COPD, neurological disorders, osteoporosis, anemia General/vital signs Pale, thin and tired cardiac cachexia, rarely in distress Heart rate: slow, fast, regular, irregular Blood pressure: high, low or normal Respiratory rate: may be tachypneic Oxygen saturation: often low-normal (90-93%) Physical Exam (cont.) HEENT Neck veins like pipes, pulsations Carotid artery bruits or referred murmur of AS? Chest Shape determines feel of precordium (quiet vs. active); quality of heart sounds Gallop (S3) heard best sitting Lungs: early vs. late inspiratory rales, dullness vs. lack of breath sounds Physical Exam (cont.) Abdomen Large tender liver Ascites (scrotal edema) Aortic, renal, iliac bruits Extemities Cold and pale, no pulses Edema, dependent rubor Peripheral neuropathy: pain and numbness Physical Exam: Function Vision and hearing Neurological Cognition, affect Body tone, strength, asymmetry (contractures) ADL level Fall risk: gait and balance Co-morbidities Diabetes: More severe peripheral vascular disease More severe peripheral neuropathy More severe visual loss More severe fluid retention (renal) Sympathetic nervous system changes Orthostatic changes Gastrointestinal complaints Labs We Need Them! Beta natriuretic peptide (BNP) Hormone elaborated by the ventricles Rises with increased volume / pressure Counteracts renin-angiotensin system (natriuresis) rises along with the NYHA classification Normal rise with age Less than 100 pg/ml (above 80 is suspicious) Women slightly higher than men (stiff ventricles) Most important prognosticator of short-term outcome* along with functional assessment *Cowie, Lancet 1997 *Maisel, NEJM 2002 Labs (cont.) Renal function BUN (pre-renal)/Creatinine (renal function) Patients tolerate BUNs that rise slowly Diabetes increases risk for renal failure Creatinine of 4 Fluid retention, hypertension, calcium/phosphate cannot be controlled with diuretics Labs (cont.) Electrolytes (reninaldosterone system) Low sodium (also a diuretic effect) Potassium Hypokalemia is common (diuretics) Hyperkalemia is deadly ACE inhibitors Acute renal decompensation Diabetes out of control High Bicarbonate (metabolic alkalosis) Low is ominous (respiratory acidosis, pending respiratory failure) Other Important Labs CBC (anemia, infection, myelodysplasia) Thyroid status Albumin, pre-albumin (nutritional status) Liver function (congestion) Oxygen saturation INRs for those on Coumadin Cardiac Imagining Echocardiogram Systolic vs. diastolic dysfunction Valvular, pericardial disease Cardiac output, wall motion abnormalities Nuclear Imagine (MUGA) More accurate measure of output, ischemia Helpful if angiogram is being considered Approach to Our CHF Patients Goals of therapy: directives What are the patient's/familys wishes? Co-morbidities play a big role! DNR Wish for hospitalization Safety vs. Independence Motivation for rehabilitation / maintenance of function Treatment of Person with CHF at Home Establish a team Patient/caregivers Contact-skilled medical provider Physician Therapists, social worker, nutritionist Set up your care plan Education Communication Role of Patient /Caregiver R E W A R D Right drug; rest periods Exercise Weigh daily Anticipate needs (safety) Reach the nurse Diet Role of the Caregiver Fill, check pillboxes Weights, vital signs as able Support healthy lifestyle Look for red flags Increased breathlessness Increased confusion Decreased energy CHF Drugs Symptom control Fluid management: signs of congestion Diuretics are still mainstay: Lasix (Bumex), zaroxalyn, aldosterone inhibitors: aldactone Watch electrolytes, BUN Watch hypotension in diastolic dysfunction Preload reduction: distended neck veins Nitrates, long-acting form Watch orthostatic hypotension CHF Drugs (cont.) ACE Inhibitors (preload and afterload) Opposes the vasoconstricting action of renin-angiotensin system Multiple studies show increased life expectancy; preservation of renal function Watch blood pressure drop Watch potassium rise Watch for cough in first generation (go to ARBs) Watch acute deterioration in renal function when combined with diuretics (creatinine) Hydralazine also induces vasodilation. CHF Drugs (cont.) Beta-blockers Down-regulate sympathetic tone rest the heart Treatment of choice for diastolic dysfunction Improvement in relaxation may take a year Multiple studies show decrease in sudden death, Possibly reduces risk of ventricular arrhythmia Good way to control fast atrial fibrillation Labetolol, carvedilol (Coreg) induce vasodilation Watch for hypotension, bradycardia CHF Drugs: Digoxin and Amiodorone Digoxin Augments contractility kicks the heart No role in diastolic dysfunction Possibly useful in systolic dysfunction Watch toxicity can be subtle: GI effects Amiodorone Reduces risk of fatal ventricular arrhythmias Also used to stabilize atrial arrhythmias Side effects in every organ system Drug-drug with Coumadin; thyroid, pulmonary CHF Drugs Calcium channel blockers Generally not recommended Early drugs (verapamil, cardizem) associated with detrimental effects. New study PRAISE study shows potential benefit from Norvasc (amlodipin) in patients with non-ischemic CHF. All patients were on ACE inhibitors PRAISE II in progress New Drugs for CHF: Nesiritide and Eplenenone Recombinant BNP as IV infusion (Natrecor) Could give at home, or ER and return home Requires careful BP monitoring Induces prompt relief of congestion, diuresis No drug-drug interaction New aldosterone-blocker: epleneone (Inspra) Action similar to spironolactone Yet to be proven superior Interventional Cardiology Includes stints, bypass, valve surgery, pacemakers, implantable defibrillators Helping families to choose What are the co-morbidities? Benefit vs. risk (second opinion!) Daily Care for CHF at Home Patient / caregivers have to be in charge. Close case management (phone) has been shown over and over to reduce rehospitalization significantly! Right meds, Rest Exercise Weigh daily Anticipate needs Reach the nurse Diet Time for Hospice? Class III or IV NYHA classification BNP probably over 200 Patients symptoms are not improving with best therapy Co-morbidities (especially COPD, dementia) further reduce quality of life Nurses role: explore the idea, possible referral to palliative care program Palliative Care for Claus After so many years of adapting, he cant agree to call it quits. However, with the help of his wife, he acknowledges that he is getting weaker. Still, he cant give up the idea of hospital rescue. The palliative care team at SMMC is seeing him weekly, educating him and winning his trust. He will form a relationship with a hospice nurse. In due time, he will hopefully elect hospice. CHF: Final Words There is only one place where congestive heart failure can be treated well enough to satisfy patients and result in decreased hospitalization: !>~.  ) Z ! 1 G n o o /8:cxb>@V\op9QqҾ׶OJQJ6CJ]aJCJ aJ CJaJCJaJCJaJCJaJCJOJQJaJB*CJaJph'B*CJaJph'B*CJ(aJ(ph'CJaJF!;>Z~.o & F & F ^` & F!+   ) Z ! 1 G S n o  & F & F & F & F   0 o /cx/Jj & F & F  & F^` & F & FNb>?@V\~#op & F & F & F9Qdq:Rv"I| & F & F & FqB E<S2H`{[4w5CJ\aJ5CJ\aJOJQJ5CJOJQJ\aJCJaJCJaJCJ aJ CJaJCJaJCJOJQJaJCJaJHpqBR .ETo. & F & F & F.=g<S}(,E] 2 & F & F & F2HR`{.H[t4L & F & F & F & FLwR Y +![!!! """ & F  & F^ & F & F & FY ""2":"c""":#####$$$%%%%%%&!&&&&y'z'''''''''''''((*+ +!+CJHOJQJaJHCJOJQJaJCJ aJ CJOJQJaJCJaJOJQJCJaJCJaJCJaJ7""2":"c"""""#:#]######$}$$$$%:%Y%%%% & F & F & F%%&!&q&&&&&'y'''''''''(J(((()** & F & F & F* +!+ ^`#0P/ =!"#$% i@@@ Normal CJOJQJ_HaJmH sH tH L`L Heading 17$8$@&H$B*CJ"OJQJaJ"ph\`\ Heading 27$8$@&H$^`B*CJOJQJaJph\`\ Heading 3x7$8$@&H$^x`B*CJOJQJaJphT`T Heading 4$7$8$@&H$^`$B*OJQJph\`\ Heading 5L7$8$@&H$^`LB*CJOJQJaJph<A@< Default Paragraph Font!'t!;>Z~.o)Z!1GSno   0 o / c x / J j N b  > ? @ V \ ~ #op9Qdq:Rv"I|pqBR .ETo.=g<S}(,E] 2HR`{.H[t4LwRY+[ 2:c:] } !:!Y!!!!!"!"q"""""#y#########$J$$$$%&& '#'0 0 0 00000000000 0( 0( 08 0Z( 0( 0(000 0  0  0 ( 0 ( 0 0 0 0 0 000 0( 0( 0 0( 08 0)8 0)0 0( 0 0( 0 0( 01( 0100 0 o( 0!( 0" 0#o( 0$( 0%( 0&( 0'( 0(0 0)o  0*o  0+o  0,o 0 0-c ( 0.x ( 0/x ( 00x ( 01x ( 02x ( 03x ( 04x 0c 0c 0 05 ( 06 ( 07 8 08N 8 09N 8 0:N 8 0;N 8 0<N (0 (0 0 0=@ ( 0>V ( 0?V  0@@ ( 0A ( 0B ( 0C 0@ 0 0Dp( 0E( 0F( 0G 0Hp( 0I( 0J( 0K0 0L9 0M9( 0Nd( 0Od 0P9 0Q90 0R( 0S( 0T( 0U( 0V( 0W8 0Xv8 0Yv0 0Z( 0[( 0\( 0]( 0^( 0_8 0`8 0a8 0b80(0(080(00 0c( 0d( 0e( 0f8 0g8 0h800 0i( 0j( 0k8 0l8 0mH0.H0.H0.( 0n8 0o0 0p 0q 0r 0s 0t 0u0 0v( 0w( 0x( 0y 0z( 0{<( 0|<0 0}( 0~8 08 08 08 08 00 0( 0( 0( 0( 0 0( 02( 020 0`( 0{( 0{( 0{( 0{( 0{( 0{800 0 0 0 0( 0H( 0H( 0H000 0( 08 08 0( 08 0w8 0w(00 0( 0( 08 0R8 0R8 0R8 0R( 000 0( 0( 0( 0( 0( 0( 0H0H0800 0( 028 0:8 0:8 0: 0( 0( 08 08 000 0( 0( 08 08 08 00 0 ( 0 ( 0 ( 0 ( 0  0 ( 0!( 0!0 0" 0"( 0q"( 0q"0 0" 0"8 0#8 0#8 0#8 0#8 0#8 0#0 0# 0# 0# 0# 0#0 0$ 0$000!+*16 .2L"%*!++-./02345789!+,SVBPdu)4(0GRS_`m! /   9D Ufozy~ .:`n,t|*3.9JMWYdr~ "'129'-D K M V n v !!~!!!!!!!!!!V"a"X#i##'Jm}###'333333Valued Gateway ClientbG:\Clinical Documentation\Power Point Slides for Webinars\Clinical Presentation CHF in Elderly.doch7*PL @CJOJQJo( @CJOJQJo(\ @CJOJQJo(  @CJOJQJo( @CJ OJQJo(X @CJOJQJo( @CJOJQJo( @ d !'@@UnknownG:Times New Roman5Symbol3& :ArialQ& Franklin Gothic Demi9Garamond[& Franklin Gothic Demi CondQ& Franklin Gothic Book;Wingdings"qh\&\&\&C D$20'&2Q Clinical Presentation in ElderlyValued Gateway ClientValued Gateway Client Oh+'0$ DP l x  !Clinical Presentation in ElderlyroslinValued Gateway Clientinalualu Normal.dotwValued Gateway Clientin1luMicrosoft Word 9.0n@Ik@^=*@@^=*C  ՜.+,0  hp  GatewayD' !Clinical Presentation in Elderly Title  !"#$%&'()*+,-./0123456789:<=>?@ABCDEFGHIJKLMNOQRSTUVWYZ[\]^_bRoot Entry F@WJd1Table; )WordDocument%tSummaryInformation(PDocumentSummaryInformation8XCompObjjObjectPool@WJ@WJ  FMicrosoft Word Document MSWordDocWord.Document.89q